Get the Stockscreener App
16.07
5.34%
0.815
After Hours:
16.37
0.30
+1.87%
Polyrizon Ltd stock is traded at $16.07, with a volume of 36,543.
It is up +5.34% in the last 24 hours and up +3.28% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$15.26
Open:
$15.2
24h Volume:
36,543
Relative Volume:
0.86
Market Cap:
$30.08M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-5.953
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
+14.95%
1M Performance:
+3.28%
6M Performance:
+413.09%
1Y Performance:
+215.10%
1-Day Range:
$15.00
$16.62
1-Week Range:
$12.60
$16.62
52-Week Range:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
16.07 | 28.56M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon Ltd. (PLRZ) Surges Over 20% — Key Resistance Level in FocusOpen Trading Community - Newser
PLRZ Technical Analysis | Trend, Signals & Chart Patterns | POLYRIZON LTD (NASDAQ:PLRZ) - ChartMill
Number of shareholders of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TipRanks
Polyrizon signs first clinical trial agreement for allergy drug By Investing.com - Investing.com India
Polyrizon Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Trial - geneonline.com
Polyrizon signs first clinical trial agreement for allergy drug - Investing.com
Polyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker Trial - TipRanks
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - The Manila Times
Polyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in Texas - Quiver Quantitative
Polyrizon (Nasdaq: PLRZ) signs first U.S. clinical site for NASARIX PL-14 allergy study - Stock Titan
Nasal spray to block airborne allergens heads to first U.S. allergy trial site - Stock Titan
TradingKey - TradingKey
Polyrizon develops nasal barrier tech to block multiple respiratory viruses amid rising viral threats - Pluang
Nasal barrier tech: how Polyrizon wants to plug gaps before vaccines - Stock Titan
The growth trajectory Polyrizon (PLRZ) is on and where it leads (+15.56%) 2026-05-08Macro Trends - newser.com
PLRZ (Polyrizon) delays full quarterly earnings release, posting no notable stock movement in today’s session.Payout Ratio - newser.com
[EFFECT] Polyrizon Ltd. SEC Filing - Stock Titan
Polyrizon submits amended claims for intranasal drug delivery patent By Investing.com - Investing.com South Africa
Polyrizon submits amended claims for intranasal drug delivery patent - Investing.com UK
Polyrizon amends patent application claims for intranasal drug delivery platform - TipRanks
Polyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) expands U.S. patent claims for intranasal drug delivery platform - Stock Titan
Polyrizon widens U.S. patent bid to cover how nasal drugs stay put - Stock Titan
Polyrizon expands U.S. patent claims for its intranasal drug delivery platform, boosting IP protection. - Pluang
MMCAP, MM Asset Mgmt (PLRZ) joint filing reports 7.3% ownership - Stock Titan
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon files European patent for intranasal drug delivery tech By Investing.com - Investing.com South Africa
Polyrizon Files European Patent Application for Trap & Target Intranasal Drug Delivery Platform - TipRanks
Polyrizon files European patent for intranasal drug delivery tech - Investing.com
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform - The Manila Times
Polyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery Technology - Quiver Quantitative
Polyrizon seeks Europe patent for system designed to keep nasal drugs in place - Stock Titan
Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo - MSN
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest - MSN
Polyrizon shares gain on plan to buy majority stake in private aviation company - MSN
Polyrizon Ltd. (PLRZ) registers 499,999 shares for resale under Form F-1 - Stock Titan
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):